临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Plerixafor (AMD3100)
中文名称:普乐沙福
CAS号:110078-46-1
分子式: C28H54N8 分子量: 502.78
产品形式: Free Base
研发状态: Not yet recruiting
研发用途: Stem Cell Transplant Complications
研究机构: AHS Cancer Control Alberta
研发日期: April 1 2024
研发阶段: Phase 2
Plerixafor (AMD3100, JM 3100, SID791) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor inhibits human immunodeficiency virus (HIV) replication.
Tepotinib (EMD 1214063)
中文名称:特泊替尼
CAS号:1100598-32-0
分子式: C29H28N6O2 分子量: 492.57
产品形式: free base
研发状态: Recruiting
研发用途: Advanced Cancer; Non Small Cell Lung Cancer
研究机构: Institute of Cancer Research United Kingdom; Merck Serono GmbH Germany; Merck Sharp & Dohme LLC
研发日期: May 3 2023
研发阶段: Phase 1
Tepotinib (EMD 1214063, MSC2156119) is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib (EMD 1214063) induces autophagy. Phase 1.
Granisetron
中文名称:格拉司琼
CAS号:109889-09-0
分子式: C18H24N4O 分子量: 312.41
产品形式: Serotonin 5-HT3 receptor
研发状态: Active not recruiting
研发用途: Chemotherapy-Induced Nausea and Vomiting (CINV)
研究机构: Heron Therapeutics
研发日期: July 6 2022
研发阶段: Phase 4
Granisetron (Sancuso, Kevatril, Granisetronum, Sustol) is a serotonin receptor (5HT-3 selective) antagonist that is used as an antiemetic and antinauseant for cancer chemotherapy.
ASP3026
中文名称:N2-[2-甲氧基-4-[4-(4-甲基-1-哌嗪基)-1-哌啶基]苯基]-N4-[2-[(1-甲基乙基)磺酰基]苯基]-1,3,5-三嗪-2,4-二胺
CAS号:1097917-15-1
分子式: C29H40N8O3S 分子量: 580.74
产品形式: free base
研发状态: Completed
研发用途: Solid Tumor
研究机构: Astellas Pharma Inc
研发日期: May-11
研发阶段: Phase 1
ASP3026 is a novel and selective inhibitor for ALK with IC50 of 3.5 nM. Phase 1.
Tovorafenib (MLN2480)
中文名称: 6-氨基-5-氯-N-[(1R)-1-[5-[[[5-氯-4-(三氟甲基)-2-吡啶基]氨基]羰基]-2-噻唑基]乙基]-4-嘧啶甲酰胺
CAS号:1096708-71-2
分子式: C17H12Cl2F3N7O2S 分子量: 506.29
产品形式: free base
研发状态: Recruiting
研发用途: Low-grade Glioma
研究机构: Daniel Morgenstern; The Hospital for Sick Children
研发日期: March 21 2024
研发阶段: Early Phase 1
Tovorafenib (MLN2480, BIIB-024, TAK580, AMG-2112819, BSK1369, DAY-101) is an oral, selective pan-Raf kinase inhibitor in chinical trials.
ARQ 621
中文名称:N-(3-氨基丙基)-3-氯-N-[(1R)-1-[7-氯-3,4-二氢-4-氧代-3-(苯基氨基)-2-喹唑啉基]-3-丁炔-1-基]-2-氟苯甲酰胺
CAS号:1095253-39-6
分子式: C28H24Cl2FN5O2 分子量: 552.43
产品形式: free base
研发状态: Completed
研发用途: Metastatic Solid Tumors Refractory/Relapsed Hematologic Malignancies
研究机构: ArQule Inc. a subsidiary of Merck Sharp & Dohme LLC a subsidiary of Merck & Co. Inc. (Rahway NJ USA)
研发日期: Aug-09
研发阶段: Phase 1
ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
